Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1
receptor agonists (GLP-1RAs) on glycaemic control, body weight, and lipid profile in adults …

Obesity is a chronic disease associated with increased risk of obesity-related complications
and mortality. Our better understanding of the weight regulation mechanisms and the role of …

Background Tirzepatide, a once weekly GIP/GLP-1 receptor agonist, reduces blood glucose
and body weight in people with type 2 diabetes. The cardiovascular (CV) safety and efficacy …

Obesity is a major public health crisis. Multi-specific peptides have emerged as promising
therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose …

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

A revolution in obesity treatment | Nature Medicine Skip to main content Thank you for visiting
nature.com. You are using a browser version with limited support for CSS. To obtain the best …

For more than a century, physicians have searched for ways to pharmacologically reduce
excess body fat. The tide has finally turned with recent advances in biochemically …

Obesity is often associated with a chronic, low-grade inflammatory state affecting the entire
body. This sustained inflammatory state disrupts the coordinated communication between …

Objective Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide
greater weight loss than agonists targeting the GLP-1 receptor alone. We report results from …

Diabetes, a complex multisystem metabolic disorder characterized by hyperglycemia, leads
to complications that reduce quality of life and increase mortality. Diabetes pathophysiology …